Downregulation of polo-like kinase 1 induces cellular senescence in human primary cells through a p53-dependent pathway

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 68, Issue 10, 2013, Pages 1145-1156

  Kim, Hee Jin ^a   Cho, Jung Hee ^a   Kim, Jae Ryong ^a  

^a Yeungnam University   (South Korea)

Author keywords

Cellular senescence; Human primary cells.; p53; Polo like kinase 1

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; TP53 PROTEIN, HUMAN; POLO LIKE KINASE 1;

ANTAGONISTS AND INHIBITORS; CELL AGING; CELL CULTURE; DOWN REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UMBILICAL VEIN ENDOTHELIAL CELL; ARTICLE; CELLULAR SENESCENCE; DRUG ANTAGONISM; HUMAN PRIMARY CELLS.;

CELL AGING; CELL CYCLE PROTEINS; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GENES, P16; GENES, P53; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

CELLULAR SENESCENCE; HUMAN PRIMARY CELLS.; P53; POLO-LIKE KINASE 1;

EID: 84884993153     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glt017     Document Type: Article

References (52)

1. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res. 1961;25:585-621.
2. Campisi J. Cellular senescence: putting the paradoxes in perspective. Curr Opin Genet Dev. 2011;21:107-112.
3. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130:223-233. (Pubitemid 47081143)
4. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37:961-976. (Pubitemid 40311739)
5. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192:547-556.
6. Schmidt S, Essmann F, Cirstea IC, et al. The centrosome and mitotic spindle apparatus in cancer and senescence. Cell Cycle. 2010;9:4469-4473.
7. Ly DH, Lockhart DJ, Lerner RA, et al. Mitotic misregulation and human aging. Science. 2000;287:2486-2492. (Pubitemid 30185444)
8. Maehara K, Takahashi K, Saitoh S. CENP-A reduction induces a p53-dependent cellular senescence response to protect cells from executing defective mitoses. Mol Cell Biol. 2010;30:2090-2104.
9. Wagner M, Hampel B, Bernhard D, et al. Replicative senescence of human endothelial cells in vitro involves G1 arrest, polyploidization and senescence-associated apoptosis. Exp Gerontol. 2001;36:1327-1347. (Pubitemid 32707871)
10. Fujisawa H, Nishikawa T, Zhu BH, et al. Accelerated aging of dermal fibroblast-like cells from the senescence-accelerated mouse (SAM): acceleration of changes in DNA ploidy associated with in vitro cellular aging. J Gerontol A Biol Sci Med Sci. 1998;53:B11-B17.
11. Walen KH. Human diploid fibroblast cells in senescence; cycling through polyploidy to mitotic cells. In Vitro Cell Dev Biol Anim. 2006;42:216-224. (Pubitemid 44744157)
12. Yang D, McCrann DJ, Nguyen H, et al. Increased polyploidy in aortic vascular smooth muscle cells during aging is marked by cellular senescence. Aging Cell. 2007;6:257-260. (Pubitemid 46455069)
13. Mukherjee AB, Thomas S. A longitudinal study of human agerelated chromosomal analysis in skin fibroblasts. Exp Cell Res. 1997;235:161-169. (Pubitemid 27381694)
14. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs. 2010;19:27-43.
15. Andrysik Z, Bernstein WZ, Deng L, et al. The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res. 2010;38:2931-2943.
16. Archambault V, Glover DM. Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol. 2009;10:265-275.
17. Liu XS, Song B, Liu X. The substrates of Plk1, beyond the functions in mitosis. Protein Cell. 2010;1:999-1010.
18. Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003;94:148-152. (Pubitemid 36575873)
19. Weichert W, Ullrich A, Schmidt M, et al. Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci. 2006;97: 271-276.
20. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA. 2003;100:5789-5794. (Pubitemid 36576886)
21. Bu Y, Yang Z, Li Q, Song F. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Oncology. 2008;74:198-206.
22. Schmit TL, Zhong W, Setaluri V, et al. Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol. 2009;129:2843-2853.
23. van Vugt MA, van de Weerdt BC, Vader G, et al. Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem. 2004;279:36841-36854. (Pubitemid 39129033)
24. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995;92:9363-9367.
25. Alcorta DA, Xiong Y, Phelps D, et al. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA. 1996;93:13742-13747. (Pubitemid 26424190)
26. Ito Y, Miyoshi E, Sasaki N, et al. Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer. 2004;90:414-418. (Pubitemid 38250638)
27. Weichert W, Schmidt M, Gekeler V, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate. 2004;60:240-245. (Pubitemid 38971835)
28. Weichert W, Kristiansen G, Winzer KJ, et al. Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch. 2005;446:442-450. (Pubitemid 40674853)
29. Jang YJ, Kim YS, Kim WH. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas. Int J Oncol. 2006;29:589-594.
30. Weichert W, Kristiansen G, Schmidt M, et al. Polo-like kinase 1 expression is a prognostic factor in human colon cancer. World J Gastroenterol. 2005;11:5644-5650. (Pubitemid 41684917)
31. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J. 2005;19:611-613. (Pubitemid 40471261)
32. Spankuch B, Matthess Y, Knecht R, et al. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst. 2004;96:862-872. (Pubitemid 38807607)
33. Gilmartin AG, Bleam MR, Richter MC, et al. Distinct concentration- dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009;69:6969-6977.
34. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst. 2002;94:1863-1877. (Pubitemid 36104631)
35. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol. 2006;26:2093-2108. (Pubitemid 43346913)
36. Lu B, Mahmud H, Maass AH, et al. The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro. PLoS ONE. 2010;5:e12963.
37. Lei M, Erikson RL. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene. 2008;27:3935-3943. (Pubitemid 351913640)
38. Lee KS, Erikson RL. Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol Cell Biol. 1997;17:3408-3417. (Pubitemid 27215056)
39. Seki A, Coppinger JA, Jang CY, et al. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science. 2008;320:1655-1658. (Pubitemid 351931258)
40. Mac?rek L, Lindqvist A, Lim D, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature. 2008;455:119-123.
41. Zhang D, Shimizu T, Araki N, et al. Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice. Oncogene. 2008;27:4305-4314. (Pubitemid 352010006)
42. Huck JJ, Zhang M, McDonald A, et al. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol Cancer Res. 2010;8:373-384.
43. Kim HJ, Cho JH, Quan H, Kim JR. Down-regulation of Aurora B kinase induces cellular senescence in human fibroblasts and endothelial cells through a p53-dependent pathway. FEBS Lett. 2011;585:3569-3576.
44. Elowe S, Hummer S, Uldschmid A, et al. Tension-sensitive Plk1 phosphorylation on BubR1 regulates the stability of kinetochore microtubule interactions. Genes Dev. 2007;21:2205-2219. (Pubitemid 47360842)
45. Baker DJ, Jeganathan KB, Cameron JD, et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nat Genet. 2004;36:744-749. (Pubitemid 38886637)
46. Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem. 2004;279:25549-25561. (Pubitemid 38756815)
47. Rajendra R, Malegaonkar D, Pungaliya P, et al. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem. 2004;279:36440-36444. (Pubitemid 39128984)
48. Liu XS, Li H, Song B, Liu X. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery. EMBO Rep. 2010;11:626-632.
49. van Vugt MA, Brás A, Medema RH. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol Cell. 2004;15:799-811. (Pubitemid 39194909)
50. Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010;9:643-660.
51. Bassermann F, Frescas D, Guardavaccaro D, et al. The Cdc14B-Cdh1- Plk1 axis controls the G2 DNA-damage-response checkpoint. Cell. 2008;134:256-267. (Pubitemid 352010329)
52. Martin BT, Strebhardt K. Polo-like kinase 1: target and regulator of transcriptional control. Cell Cycle. 2006;5:2881-2885. (Pubitemid 44953940)